Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PRCP | P42785 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29903416 | 1.00 | MEN1 (0.49) | MEN1KMT2AMAPTLMNANPC1 | |
| SCHEMBL6436184 | 1.00 | MEN1 (0.49) | MEN1KMT2AMAPTLMNANPC1 | |
| SCHEMBL17634260 | 0.86 | GAA (0.40) | MEN1KMT2AMAPTLMNANPC1 | |
| SCHEMBL11334202 | 0.86 | CYP19A1 (0.47) | MEN1KMT2AMAPTLMNANPC1 | |
| SCHEMBL17634160 | 0.82 | PARP1 (0.49) | MEN1KMT2AMAPTLMNAGAA | |
| SCHEMBL11345138 | 0.80 | CYP19A1 (0.50) | MEN1KMT2AMAPTLMNANPC1 | |
| SCHEMBL11341890 | 0.80 | CYP19A1 (0.49) | MEN1KMT2AMAPTNPC1GAA | |
| SCHEMBL23558715 | 0.79 | SMN1; SMN2 (0.46) | MEN1KMT2AMAPTLMNANPC1 | |
| SCHEMBL2378790 | 0.77 | AR (0.46) | MEN1KMT2AMAPTLMNANPC1 | |
| SCHEMBL6984099 | 0.77 | CYP19A1 (0.52) | MEN1KMT2AMAPTNPC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115028598-B | Synthesis method of 3-trifluoromethyl-4H-benzo [ b ] [1,4] oxazine compound | 南通大学 | 2024-02-23 | — | — | CN | disclosed |
| CN-115028598-A | Synthetic method of 3-trifluoromethyl-4H-benzo [ b ] [1,4] oxazine compound | 南通大学 | 2022-09-09 | — | — | CN | disclosed |
| WO-2016124704-A1 | BLUE FLUORESCENT EMITTERS | Technische Universität Dresden (DE) | 2016-08-11 | — | — | WO | disclosed |
| US-20070043024-A1 | Azacyclic compounds as inhibitors of sensory neurone specific channels | IONIX PHARMACEUTICALS LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
| EP-1660454-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC CHANNELS | Vernalis (R&D) Limited (GB) | 2006-05-31 | — | — | EP | disclosed |
| US-6932961-B1 | Oxazinocarbazoles for the treatment of CNS diseases | PHARMACIA & UPJOHN COMPANY (US) | 2005-08-23 | — | — | US | disclosed |
| WO-2005005392-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC CHANNELS | IONIX PHARMACEUTICALS LIMITED (GB) | 2005-01-20 | — | — | WO | disclosed |
| EP-1495031-A1 | LABELED OXAZINOCARBAZOLES AS DIAGNOSTIC AGENTS | Pharmacia & Upjohn Company LLC (US) | 2005-01-12 | — | — | EP | disclosed |
| US-6821970-B2 | USEFUL FOR TREATING DISEASES WHEREIN MODULATION OF 5-HT ACTIVITY IS DESIRED; NERVOUS SYSTEM DISORDERS | PHARMACIA & UPJOHN COMPANY | 2004-11-23 | — | — | US | disclosed |
| CN-1165539-C | Oxazinocarbazoles for the treatment of CNS diseases | �������Ŷ���Լ��������˾ | 2004-09-08 | — | — | CN | disclosed |
| CN-1155542-A | Process for preparation of novel cyclic anthranilic acid derivatives | KYORIN SEIYAKU KK (JP) | 1997-07-30 | — | — | CN | disclosed |
| EP-0310096-B1 | Novel cyclic anthranilic acid derivatives and process for their preparation | KYORIN SEIYAKU KK (JP) | 1995-04-19 | — | — | EP | disclosed |
| US-5281600-A | Antiinflammatory agents, rheumatic diseases and immunomodulators | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1994-01-25 | — | — | US | disclosed |
| US-5147874-A | Antiarthritic agents | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1992-09-15 | — | — | US | disclosed |
| US-4956372-A | ANTIRHEUMATOID AND IMMUNOMODULATORS | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1990-09-11 | — | — | US | disclosed |
| CN-1032788-A | Novel cyclic anthranilic acid derivatives and process for preparing same | KYORIN SEIYAKU KK (JP) | 1989-05-10 | — | — | CN | disclosed |
| EP-0310096-A2 | Novel cyclic anthranilic acid derivatives and process for their preparation | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1989-04-05 | — | — | EP | disclosed |
| EP-0015872-B1 | CATIONIC AZODYESTUFFS, THEIR PREPARATION AND THEIR USE IN DYEING AND PRINTING TEXTILE MATERIAL | CIBA-GEIGY AG (CH) | 1983-03-30 | — | — | EP | disclosed |
| US-4288589-A | Cationic dyes | CIBA-GEIGY CORPORATION (US) | 1981-09-08 | — | — | US | disclosed |
| EP-0015872-A1 | Cationic azodyestuffs, their preparation and their use in dyeing and printing textile material | CIBA-GEIGY AG (CH) | 1980-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043024-A1 | Azacyclic compounds as inhibitors of sensory neurone specific channels | SCN1B, SCN1A, SCN10A | MEN1 2444/4885KMT2A 2911/4885MAPT 2361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.